Belzutifan is a really strong and picky， targeting something called HIF-2α. This thing is key in dealing with VHL-related kidney cancer. The drug works by cutting down on the signals that make tumors hungry for oxygen.
That’s a pretty common issue in RCC and other solid tumors. It comes as a tablet, with each one packing 40 mg of the good stuff. Doctors usually suggest taking 120 mg a day, and that’s three tablets.
You get these in bottles with 90 tablets each.
Reviews
There are no reviews yet.